# Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma

> **NCT04595994** · PHASE1 · RECRUITING · sponsor: **Grupo Espanol de Investigacion en Sarcomas** · enrollment: 14 (estimated)

## Conditions studied

- Sarcoma,Soft Tissue

## Interventions

- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT04595994
- **Lead sponsor:** Grupo Espanol de Investigacion en Sarcomas
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-02
- **Primary completion:** 2025-11-30
- **Final completion:** 2026-05-31
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04595994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04595994, "Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04595994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*